REACH Orphan Substances Consortium
Lifetime
10 annual accounts with figures on one time axisKey points
from the 2025 annual accountsFilings
The 2020 accounts came 15 days late. The other nine were filed on time.
Position in the sector
Lower solvency than 85% of companies in other professional activities. Sector median 42.8% · 732 companies.
Bankruptcy probability
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| REACH Orphan Substances Consortium Vosselaar | €1.2m | -€6,176 | 0.5% | - |
| ZORGLANDSCHAP Antwerp | €1.0m | -€1,128 | 11.6% | 0 |
| Virtual Physiological Human Institute for Integrative Biomedical Research Leuven | €1.2m | -€124,194 | 8.2% | - |
| ZAPPASS Herenthout | €2.0m | -€85,326 | 26.5% | - |
| Ecorus BE Diest | €1.5m | -€144,091 | -22.9% | - |
| CATALYA Liège | €1.2m | -€22,818 | 86.4% | - |
| European Calcified Tissue Society Ixelles | €0.9m | -€65,060 | 92.0% | - |
These companies have the same main activity as REACH Orphan Substances Consortium: other professional, scientific and technical activities (NACE 74999). They are comparable in size and age: total assets between €879,000 and €2m, founded between 2010 and 2019.
Official details
Source: KBO- Status
- Active since 21-05-2015Normal situation
- Activity
- Other professional, scientific and technical activitiesNACE 74999and 1 other
- Establishment unit
- 2.242.797.5742350 Vosselaar, registered on 25-05-2015
- Financial year end
- 31 December
- Peppol
- Reachable since 12-11-2025
Annual accounts 2025
- €1.2m▲ 18.8%
- Filing
- Filed on 30-07-2026, 1 day before the end of the filing period
Insights on REACH Orphan Substances Consortium
REACH Orphan Substances Consortium files the abbreviated format. That format states no turnover. The gross margin fell from €8 in 2016 to -€6,176 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about REACH Orphan Substances Consortium
- What is the company number of REACH Orphan Substances Consortium?
- The company number of REACH Orphan Substances Consortium is 0630.838.609. The VAT number is the same number with BE in front: BE 0630.838.609.
- Where is REACH Orphan Substances Consortium based?
- The registered office is at Haverstraat 8, 2350 Vosselaar.Company details
- What does REACH Orphan Substances Consortium do?
- According to the KBO register, the main activity is other professional, scientific and technical activities (NACE 74999).
- What is the legal form of REACH Orphan Substances Consortium?
- REACH Orphan Substances Consortium is a private limited company (BV).
- When was REACH Orphan Substances Consortium founded?
- REACH Orphan Substances Consortium was founded on 21-05-2015.
- Is REACH Orphan Substances Consortium still active?
- Yes, REACH Orphan Substances Consortium is an active enterprise in the KBO register.
- What is the turnover of REACH Orphan Substances Consortium?
- The annual accounts for financial year 2025 state no turnover. The abbreviated format does not require it. In financial year 2020 turnover was €758,883.Financials
- Where can I find the annual accounts of REACH Orphan Substances Consortium?
- REACH Orphan Substances Consortium filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of REACH Orphan Substances Consortium due?
- REACH Orphan Substances Consortium must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.